Chris Liang, Ph.D., EVP and Chief Scientific Officer
Chris Liang, Ph.D., is the co-founder of Xcovery. He is a leading scientist in the design of protein kinase inhibitors who has authored more than 40 scientific publications and secured more than 50 patents. Dr. Liang is co-developer of Sutent®, an FDA approved multi-kinases inhibitor for Gleevec®-resistant gastrointestinal stromal tumors and renal cell carcinoma, which he developed while serving as director of medicinal chemistry at SUGEN. SUGEN and Sutent® were acquired by Pfizer. Additionally, Dr. Liang served as director of medicinal chemistry at Scripps Research Institute in Florida before joining Tyrogenex.
Dr. Liang’s research focuses on the design of protein kinase inhibitors by combining computational modeling, medicinal chemistry and broad knowledge in other areas of drug discovery. His recent work has focused on the reduction of toxicity in existing multi-kinase inhibitors. Dr. Liang holds a Ph.D. in theoretical chemistry from Princeton University in 1989.
James Gibbons, Ph.D., Vice President, Oncology
Jay Gibbons, Ph.D., is responsible for the transitional development of Xcovery’s preclinical drug candidates through IND-enabling studies and Phase 1 human clinical trials. With more than 25 years experience in translational oncology research and deep expertise in the PI3K/mTor signaling pathway, he has authored more than 50 scientific publications and has secured nine patents. Prior to joining Tyrogenex in 2010, Dr. Gibbons served as associate vice president of oncology research at Wyeth Research. In this role, he was instrumental in filing eight INDs and the NDA for Torisel (temsirolimus), currently approved for the treatment of renal cell carcinoma.
Dr. Gibbons holds a Ph.D. in pathology from St. Louis University. He completed his post-doctoral fellowship at Cornell University Medical School, Department of Medicine, division of allergy and immunology.
Kimberly Harrow, MBA, Vice President, Clinical Operations
Kimberly Harrow has been with Xcovery since its founding. Ms. Harrow has more than 15 years of oncology research experience, which includes leading the successful submission of the company’s first investigational new drug submission. Ms. Harrow manages development and vendor relations for all of Xcovery’s development programs, including the operational oversight of Xcovery’s clinical programs. Prior to joining Xcovery, Ms. Harrow was instrumental in building the commercial operations and subsequent product launches for the portfolio companies of BioCatalyst.
Ms. Harrow holds an MBA and B.S. in biology from the University of Florida.